Pfizer and Merck KGaA with a study report (90 days)
With the recent Goblet and Adlai results, we can all speculate what will happen to Bracelet-1 trial at 16 weeks.
There should be plenty of of Partial response (PR) and Stable disease (SD). Enough to trigger interest from both Pfizer and Merck KGaA to do something. In any case, the market will bet on a deal (speculative/assume the positive).
Share price isn't going lower here, but higher.
Speculative buy will trickle in at first.
More positive analyst reports will come in.
This baby is going up